Title:
【発明の名称】MMPおよびTNF抑制剤としてのアリールスルホニルヒドロキサム酸誘導体
Document Type and Number:
Japanese Patent JP3053222
Kind Code:
B2
Abstract:
PCT No. PCT/IB95/00279 Sec. 371 Date Oct. 7, 1997 Sec. 102(e) Date Oct. 7, 1997 PCT Filed Apr. 20, 1995 PCT Pub. No. WO96/33172 PCT Pub. Date Oct. 24, 1996A compound of the formula I wherein R1, R2 R3, R4 R5, R6, R7, R8, R9 and Ar are as defined above, useful in the treatment of a condition seiected from the group consisting of arthritis, cancer, tisuue ulceration, restenosis, periodontal disease, epidermolysis bullosa, scleritis and other disease characterized by matrix metalloproteinase activity, as well as AIDS, sepsis, septic shock and other diseases involving the production of TNF.
Inventors:
Anthony Dee, Piscopio
Ritzy, James Pee
Ritzy, James Pee
Application Number:
JP53157596A
Publication Date:
June 19, 2000
Filing Date:
April 20, 1995
Export Citation:
Assignee:
Pfizer Inc.
International Classes:
C07D211/60; A61K31/33; A61K31/35; A61K31/395; A61K31/435; A61K31/44; A61K31/445; A61K31/451; A61K31/455; A61K31/495; A61K31/535; A61K31/5375; A61K31/54; A61P1/02; A61P19/02; A61P31/04; A61P31/12; A61P31/18; A61P35/00; A61P37/04; A61P43/00; C07D211/78; C07D211/84; C07D211/96; C07D213/60; C07D239/04; C07D241/04; C07D241/06; C07D241/08; C07D241/50; C07D265/06; C07D265/08; C07D265/30; C07D265/32; C07D279/06; C07D279/12; C07D295/24; C07D327/06; C07D401/00; C07D401/04; C07D401/06; C07D403/00; C07D405/00; C07D409/00; C07D409/06; C07D413/00; C07D413/04; C07D417/00; C07D417/06; C07D453/02; C07D471/10; C07D473/00; C07D491/10; C07D495/10; A61K; C07D; (IPC1-7): C07D211/96; A61K31/445; A61K31/535; A61P1/02; A61P31/04; A61P31/12; A61P37/04; A61P43/00; C07D241/04; C07D265/30
Attorney, Agent or Firm:
Kazuo Shamoto (4 outside)